Gansu Foci In Medicinal Materials Co., Ltd. announced that it expects to receive CNY 40 million in funding from LanZhou Foci Pharmaceutical Co.,Ltd.
January 02, 2020
Share
Gansu Foci In Medicinal Materials Co., Ltd. announced that it will receive CNY 40 million in an equity round of funding on January 2, 2020. The transaction will include participation from returning investor LanZhou Foci Pharmaceutical Co.,Ltd. (SZSE:002644) who will retain 100% stake in the company. The transaction has been approved at the first meeting of the seventh board of directors of the investor. Post to the transaction, the registered capital of the company will increase from CNY 10 million to CNY 50 million.
LanZhou Foci Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs and large health products. The Companyâs main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The Company distributes its products under the brand names Foci, Baolu and Mianshan. The Company is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The Company distributes its products in domestic market and to overseas markets.
LANZHOU FOCI PHARMACEUTICAL CO.,LTD. 
